AstraZeneca, a global biopharmaceutical and biotechnology company, are looking to develop innovative approaches to obtain a more complete picture of the folding of short and long reads to reveal interactions that create unique, higher order folding structures.
Therapeutic targeting of RNA is an important and growing field of drug discovery. However, progress has been limited by a lack of understanding of RNA tertiary structure, in particular, of druggable binding sites.
AstraZeneca are seeking partners who can help develop AI/physics-based methodologies...